Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
54
ENLV Quote, Financials, Valuation and Earnings
Last price:
$1.15
Seasonality move
:
5.29%
Day range:
$1.06 - $1.18
52-week range:
$0.83 - $2.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.61x
Volume:
940.2K
Avg. volume:
7.5M
1-year change:
-10.77%
Market cap:
$28.2M
Revenue:
--
EPS (TTM):
-$0.53
Analysts' Opinion
-
Consensus RatingEnlivex Therapeutics Ltd. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, Enlivex Therapeutics Ltd. has an estimated upside of 503.45% from its current price of $1.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $1.16.
Fair Value
-
According to the consensus of 2 analysts, Enlivex Therapeutics Ltd. has 503.45% upside to fair value with a price target of $7.00 per share.
ENLV vs. S&P 500
-
Over the past 5 trading days, Enlivex Therapeutics Ltd. has overperformed the S&P 500 by 28.74% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Enlivex Therapeutics Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enlivex Therapeutics Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Enlivex Therapeutics Ltd. reported revenues of --.
Earnings Growth
-
Enlivex Therapeutics Ltd. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Enlivex Therapeutics Ltd. reported earnings per share of -$0.09.
Enterprise value:
10.6M
EV / Invested capital:
0.58x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$292K
Return On Assets:
-50.78%
Net Income Margin (TTM):
--
Return On Equity:
-59.16%
Return On Invested Capital:
-57.56%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$856K | -$709K | -$292K | -$161K | -$81K | |
| Operating Income | -$21.3M | -$16.1M | -$14.6M | -$3.1M | -$2.6M | |
| EBITDA | -$20.4M | -$15.4M | -$14.3M | -$3M | -$2.5M | |
| Diluted EPS | -$1.47 | -$0.99 | -$0.53 | -$0.12 | -$0.09 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $90.3M | $59.2M | $31.8M | $27.1M | $19.5M | |
| Total Assets | $98.2M | $72.4M | $46.9M | $29.8M | $20.9M | |
| Current Liabilities | $4.7M | $4.5M | $4.3M | $2.8M | $3M | |
| Total Liabilities | $10.1M | $9.1M | $8.2M | $3.2M | $3.5M | |
| Total Equity | $88.1M | $63.3M | $38.8M | $26.6M | $17.5M | |
| Total Debt | $6M | $4.6M | $3.8M | $419K | $426K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.2M | -$13.9M | -$12.3M | -$2.6M | -$2.3M | |
| Cash From Investing | -$32.4M | $9.8M | $11.8M | $1.4M | $4.2M | |
| Cash From Financing | $347.6K | $5.2M | $1.9M | $270.3K | $376.1K | |
| Free Cash Flow | -$24.8M | -$14M | -$12.4M | -$2.6M | -$2.3M | |
ENLV
Sector
Market Cap
$28.2M
$28.8M
Price % of 52-Week High
55.24%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-7.24%
-1.32%
1-Year Price Total Return
-10.77%
-20.64%
Beta (5-Year)
1.491
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.00
200-day SMA
Buy
Level
$1.08
Bollinger Bands (100)
Buy
Level
0.95 - 1.31
Chaikin Money Flow
Sell
Level
-195.9M
20-day SMA
Buy
Level
$0.99
Relative Strength Index (RSI14)
Buy
Level
63.00
ADX Line
Buy
Level
33.54
Williams %R
Neutral
Level
-66.4146
50-day SMA
Buy
Level
$1.04
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
204.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.2655)
Sell
CA Score
(Annual)
Level (-1.1131)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.9167)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Stock Forecast FAQ
In the current month, ENLV has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ENLV average analyst price target in the past 3 months is $7.00.
-
Where Will Enlivex Therapeutics Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enlivex Therapeutics Ltd. share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Enlivex Therapeutics Ltd.?
Analysts are divided on their view about Enlivex Therapeutics Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enlivex Therapeutics Ltd. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Enlivex Therapeutics Ltd.'s Price Target?
The price target for Enlivex Therapeutics Ltd. over the next 1-year time period is forecast to be $7.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ENLV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enlivex Therapeutics Ltd. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ENLV?
You can purchase shares of Enlivex Therapeutics Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enlivex Therapeutics Ltd. shares.
-
What Is The Enlivex Therapeutics Ltd. Share Price Today?
Enlivex Therapeutics Ltd. was last trading at $1.15 per share. This represents the most recent stock quote for Enlivex Therapeutics Ltd.. Yesterday, Enlivex Therapeutics Ltd. closed at $1.16 per share.
-
How To Buy Enlivex Therapeutics Ltd. Stock Online?
In order to purchase Enlivex Therapeutics Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ENLV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ENLV
Sector
P/E ratio
--
23.71x
PEG ratio
--
-0.01x
P/B ratio
1.61x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
ENLV
Sector
Revenue growth
--
4.85%
Earnings growth
25.02%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.12
-$0.20
Profitability
ENLV
Sector
Profitability FY 2024
-$545K
$3.6M
Return on invested capital
-57.56%
-30.98%
Return on assets
-50.78%
-27.62%
Return on equity
-59.16%
-36.69%
Earnings Date
Last Earnings Date
Nov
18
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
ENLV
Sector
Total cash
$18.3M
$27.2M
Short term investments
$20.2M
$25.7M
Total assets
$27.7M
$79.7M
Long term debt
$426K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.09% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.51% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.63% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
